BlueCatBio

Executive Summary

BlueCatBio provides the Blue Washer, a lab automation platform that has become the new standard for media exchange in cellular assays and no-tip magnetic bead separation in NGS library preparation. Since winning new product awards at SLAS and MipTec in 2015, the company has gained adoption among the top 25 pharmaceutical companies and leading clinical diagnostics labs. Their technology improves data quality in cell-based assays while reducing consumable costs and processing time for NGS workflows. Despite being a relatively young company founded in 2018, BlueCatBio's products are integrated into high-throughput screening and next-generation sequencing pipelines, positioning it as a key enabler in drug discovery and clinical genomics. The company is privately held and based in San Diego, with no disclosed funding, suggesting a lean, revenue-driven growth model. As the demand for cost-effective, high-quality lab automation grows, BlueCatBio is well placed to expand its installed base and capture a larger share of the cell therapy and gene therapy tool markets.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation Blue Washer with Enhanced Throughput and AI-Driven Optimization70% success
• Q2 2027Strategic Partnership with Major NGS Reagent Supplier for Integrated Workflow Solutions50% success
• Q3 2027Expansion into Cell Therapy Manufacturing with GMP-Certified Washer Model40% success